OncoMatch/Clinical Trials/NCT06372626

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Is NCT06372626 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ZG005 and Etoposide for neuroendocrine carcinoma.

Phase 1/2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT06372626Data as of May 2026

Treatment: ZG005 · Etoposide · Cisplatin — The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify